Can you advertise medicinal cannabis in Australia?

Medicinal cannabis advertising in Australia is heavily restricted under the TGA framework and AHPRA National Law. Schedule 8 products cannot be promoted directly to consumers. Marketing must use unbranded strategies, educational content, and B2B prescriber outreach that comply with TGO 93 and AHPRA advertising guidelines to avoid significant financial penalties.

What is TGO 93 and how does it affect medicinal cannabis marketing?

TGO 93 (Therapeutic Goods Order No. 93) is the TGA's standard governing prescription medicine information. It restricts how Schedule 8 medicines, including medicinal cannabis, can be promoted. Direct-to-consumer advertising of prescription medications is prohibited. Compliant marketing must avoid efficacy or benefit claims entirely and focus on unbranded patient education or approved B2B prescriber communication.

What is a medicinal cannabis marketing agency?

A medicinal cannabis marketing agency is a specialist firm that develops marketing strategies for cannabis clinics, cultivators, and brands within Australia's regulated framework. Unlike general agencies, a specialist firm understands TGA compliance, AHPRA advertising rules, Schedule 8 promotion restrictions, and how to build patient acquisition and prescriber outreach systems that scale without regulatory risk.

How can medicinal cannabis clinics acquire patients legally in Australia?

Medicinal cannabis clinics in Australia can legally acquire patients through unbranded, condition-focused content marketing that educates patients on treatment options without directly promoting specific products. High-intent SEO targeting condition-based search terms, compliant landing pages, and referral-based funnels are the primary legal channels. All patient-facing content must avoid claims that breach AHPRA or TGA guidelines.

What are AHPRA's advertising rules for healthcare?

AHPRA prohibits testimonials that create unreasonable expectations, claims of guaranteed outcomes, misleading comparisons, and use of specialist titles without appropriate registration. For medicinal cannabis marketing, AHPRA compliance is critical — breaches can result in significant fines, registration conditions, or public regulatory findings against the practitioner or business.

Does SEKHN work with international brands entering the Australian cannabis market?

Yes. SEKHN provides Australian market entry strategy for international medicinal cannabis and healthcare brands, covering regulatory navigation, brand restructuring for the Australian context, and compliant growth architecture. Australia's medicinal cannabis market requires specific compliance knowledge that most international agencies do not possess.

What is a healthcare marketing agency and what does SEKHN do differently?

A healthcare marketing agency develops and executes marketing strategies for businesses operating in the health sector — including clinics, telehealth providers, allied health practices, pharmaceutical brands, and medicinal cannabis businesses. SEKHN differs by engineering every strategy, campaign, and content asset from the ground up around the regulatory realities of the Australian market, including AHPRA advertising guidelines, TGA regulations, and Schedule 8 product promotion restrictions.

Do I need a healthcare marketing agency or can a general digital agency handle my needs?

If your business operates under AHPRA or TGA jurisdiction, a general digital agency carries meaningful risk. A single non-compliant ad, a reshared testimonial that breaches guidelines, or a landing page with promotional language about a Schedule 8 product can constitute a regulatory breach with serious consequences. A specialist healthcare marketing agency with genuine compliance expertise removes that risk while still delivering the performance outcomes your business needs.

What types of healthcare businesses does SEKHN work with?

SEKHN works with medicinal cannabis businesses including licensed cultivators, clinics, and dispensaries; allied health practices across physiotherapy, psychology, occupational therapy, and related disciplines; cosmetic and dermatology clinics; dental practices; telehealth providers; pharmacies; and international healthcare brands entering the Australian market.

What does a healthcare marketing agency in Australia cost?

Pricing for a specialist healthcare marketing agency varies based on scope, channel mix, and the complexity of your regulatory environment. SEKHN works on a strategic retainer model tailored to each client's growth stage and objectives, beginning with a complimentary 30-minute strategy briefing.

How does SEKHN ensure marketing compliance with TGA and AHPRA regulations?

Compliance is the starting point of everything SEKHN builds, not a final check. Every campaign, landing page, content asset, and ad creative is assessed against TGA and AHPRA regulatory standards before going live. For medicinal cannabis clients, this includes specific attention to TGO 93, unbranded content requirements, and Schedule 8 product promotion restrictions.

Where is SEKHN based and do you work with clients outside Sydney?

SEKHN is headquartered in Sydney, NSW, and works with healthcare businesses across Australia including Melbourne, Brisbane, and Perth, as well as international brands entering the Australian healthcare market.

How quickly can a healthcare marketing agency deliver results?

Paid media and funnel optimisation typically produce measurable improvement within 30 to 90 days — most clients see a 30 to 60 percent improvement in booking conversion within that window. SEO and content-led strategies build over three to six months and produce compounding returns over time.

Australia's Medicinal Cannabis Industry Is Being Built Like a Tech Startup

rytashasekhon
3 days ago
3 min read

And is that actually bad?

Australia first legalised medicinal cannabis in 2016. What followed afterwards was a startup land grab – everyone wanted (and still wants) a piece of the pie.

Telehealth platforms, vertically integrated dispensaries, and founder-led content machines have carved up one of the fastest-growing healthcare sectors in the country, borrowing the playbooks of Silicon Valley rather than the pharmacy industry.

The result? An industry that evolves fast, builds both recklessly and boldly, and carries some tensions worth examining.

The Startling Growth Numbers

The benchmark story is Montu. Founded in Melbourne in 2019, Montu claimed the top spot on Deloitte's Technology Fast 50 with revenue growth of over 20,000% between 2020 and 2022 – joining a list of previous winners that includes Afterpay, Atlassian, and Menulog. They then made history by winning back-to-back in 2023 with growth approaching 10,000%, the first company to do so in the program's 23-year history.

Perhaps the key driver to Montu's somewhat insane growth was their divergence from merely building a better pharmacy and instead, thinking like a platform: telehealth clinic Alternaleaf, pharmacy dispensing via Leafio, and clinician education through SAGED. Identify a fragmented market, own the whole stack, grow revenue per user across the entire funnel. The classic SF tech startup starter pack.

Founder-Led Content as a Brand Strategy

Founder-led content is not a term that needs defining. After all, it seems everyone (and their dog) is on Instagram and/or TikTok trying to document their journey as an aspirational entrepreneur. But, easykind was ahead of the game. If Montu represents the venture-scale playbook, easykind represents something more interesting: the founder-led, community-driven approach to building trust in a space where conventional advertising is essentially illegal.

Commencing clinically in August 2022, co-founders James and Charlie Fitsioris built one of Australia's largest medicinal cannabis providers from a Melbourne bedroom during COVID. Their solution to the marketing restrictions was the make the founders part of the brand.

Charlie has written openly on LinkedIn about the daily challenge of marketing a regulated healthcare service without being able to discuss the product, the outcomes, or the patients it helps – turning that constraint itself into content.

The Medicinal Cannabis Closed-Loop Clinic Ecosystem: Powerful and Problematic

The most structurally significant development in this sector is the rise of what could be called the closed-loop clinic ecosystem – proprietary platforms where consultation booking, product visibility, ordering pathways, and dispensing options are all housed within a single company's system.

The mechanics are straightforward. Montu owns Alternaleaf (telehealth), Leafio (dispensing), and its own product catalogue. Nectar Brands owns both the telehealth clinic Polln and the cannabis supplier Cultiva. Easykind operates under Green Australia Wholesale, which also supplies cannabis products. When a patient consults, the products they're shown, the ordering flow they follow, and the pharmacy they're sent to are all assets of the same parent company.

These closed systems have enabled genuinely fast, low-friction patient experiences – seamless booking, express delivery, ongoing care portals – that Australia's fragmented public health system couldn't provide. For many patients accessing treatment for chronic pain, anxiety, or insomnia for the first time, this end-to-end experience has been meaningfully better than the alternative.

However, there is a downside.

When the platform that consults you also sells the medicine it prescribes, clinical impartiality becomes structurally compromised. Researchers at the University of Melbourne have raised concerns that this model potentially undermines the Hippocratic oath by removing impartiality from the prescription decision. A 2025 investigation found that many of these platforms conducted consultations lasting under eight minutes – in some cases under four – with no exploration of alternative treatments. The product a patient sees isn't the full market; it's a curated catalogue from the parent company's suppliers. The ordering pathway isn't neutral; it's optimised for conversion.

This is the classic argument used by critics of the closed-loop system – you cannot run a healthcare clinic using startup logic. Why? because patient outcomes and prescription quality can't be A/B tested. For SaaS products, bad UX decisions mean inflated churn. But for medicinal cannabis clinics, they can lead to someone getting the wrong treatment.

The Honest Scorecard

What startup culture has given this sector: speed to market, genuine accessibility for patients who previously had no options, creative brand-building under severe marketing restrictions, equity crowdfunding as a community-ownership tool, and platform thinking that's driven real clinical infrastructure. Cannaponics alone raised nearly $7 million across two Birchal crowdfunding campaigns, turning patients into shareholders.

What it's taken: consultation quality under pressure from growth targets, product neutrality lost to vertical integration, and a regulatory grey zone that the TGA and ODC are beginning to address seriously. A 2025 study found that almost half of the 54 Australian medicinal cannabis websites examined were breaking regulatory guidelines.